8-K: Viracta Therapeutics Reports Q3 2024 Results, Prioritizes Lymphoma Program

Viracta Therapeutics announced its third quarter 2024 financial results, a reprioritization of resources towards its lymphoma program, and provided updates on its clinical trials.

Summary

• Viracta Therapeutics reported a net loss of $10.6 million for the third quarter of 2024, compared to a $12.6 million loss in the same period of 2023.
• The company's cash, cash equivalents, and short-term investments totaled $21.1 million as of September 30, 2024.
• Viracta expects its current cash position to fund operations into late Q1 2025.
• Research and development expenses decreased to $7.2 million for the quarter, down from $8.2 million in Q3 2023.
• The company has reprioritized resources to focus on the development of Nana-val in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL).
• A reduction in force affecting approximately 42% of employees was implemented to reduce costs.
• The company plans to report data from the expansion phase of the Phase 2 NAVAL-1 clinical trial in the first half of 2025.
• A recommended Phase 2 dose of Nana-val has been determined for patients with advanced EBV-positive solid tumors, although this program is currently paused.
• Viracta is planning a randomized controlled trial for the second half of 2025, subject to obtaining financing.
• The company aims to file a New Drug Application (NDA) for accelerated approval in 2026, contingent on securing necessary funding.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. While there is progress in clinical trials and a focus on a specific area, the financial situation and the need for additional funding, along with the significant reduction in force, create a negative sentiment.

Positives

• The company's net loss decreased compared to the same quarter last year.
• Research and development expenses have decreased, indicating cost-saving measures.
• Viracta has determined a recommended Phase 2 dose for Nana-val in advanced EBV-positive solid tumors.
• The company has a clear regulatory path forward for Nana-val in EBV-positive PTCL.
• The company is on track to report data from the expansion phase of the Phase 2 NAVAL-1 clinical trial in the first half of 2025.
• The company has received productive feedback from the FDA regarding the regulatory path for Nana-val.

Negatives

• The company's cash position is $21.1 million, which is expected to fund operations only into late Q1 2025.
• A significant reduction in force of 42% was implemented.
• The EBV-positive solid tumor program has been paused.
• The company's plans are subject to obtaining additional financing.
• The company has reduced the size of its Board of Directors from 10 to 6 seats.

Risks

• Viracta's ability to continue as a going concern is dependent on securing additional funding.
• The company's clinical trials are subject to risks related to patient enrollment and successful completion.
• There is a risk that previous clinical results may not be predictive of future outcomes.
• The company's ability to manufacture and supply nanatinostat and valganciclovir for clinical testing is a risk.
• The company's plans are subject to obtaining additional financing.
• The company's ability to file a New Drug Application (NDA) in 2026 is contingent on securing necessary funding.

Future Outlook

Viracta plans to focus on the development of Nana-val in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL), with a goal to file a New Drug Application (NDA) in 2026, subject to obtaining requisite funding. The company also plans to initiate a randomized controlled trial in the second half of 2025, contingent on securing financing.

Management Comments

• Mark Rothera, President and Chief Executive Officer of Viracta, stated that the company has sharpened its focus on the second-line EBV-positive PTCL subpopulation in the NAVAL-1 trials expansion phase.
• Mark Rothera also mentioned that the company has reprioritized resources to reduce cash burn and support the NAVAL-1 trial and a planned randomized controlled trial.
• Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer of Viracta, stated that a recommended Phase 2 dose has been determined for Nana-val in patients with advanced EBV-positive solid tumors.

Industry Context

The focus on EBV-positive PTCL aligns with the unmet medical need for targeted therapies in this area, as there are currently no approved treatments specific for this condition. The company's approach to targeting virus-associated cancers is a growing area of interest in the oncology field.

Comparison to Industry Standards

• The median progression-free survival and median overall survival times for R/R PTCL are reported to be 3.7 and 6.5 months, respectively, highlighting the need for new therapies.
• The company's focus on EBV-positive PTCL is notable as approximately 40% to 65% of PTCL is associated with EBV, and outcomes for patients with EBV+ PTCL are inferior to those whose disease is EBV-negative.
• Other companies such as Seagen and Takeda are also developing therapies for lymphomas, but Viracta's approach is unique in targeting EBV-associated malignancies.
• The company's planned randomized controlled trial is a standard approach for evaluating new therapies in oncology, similar to trials conducted by other pharmaceutical companies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the company's financial position and the need for additional funding.
• Employees have been significantly impacted by the reduction in force.
• Patients with EBV-positive PTCL may benefit from the company's focus on developing Nana-val.
• The company's suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• Meet with the FDA to finalize the proposed RCT design in the first half of 2025.
• Initiate the RCT in the second half of 2025.
• Report preliminary data from the expansion phase of the NAVAL-1 trial in the first half of 2025.
• Report Stage 1 data from patients with R/R EBV+ diffuse large B-cell lymphoma (DLBCL) in the first half of 2025.
• Present interim analysis outcomes from the NAVAL-1 trials expansion phase in 2026.
• File NDA for accelerated approval in 2026 based on interim analysis of the NAVAL-1 trials expansion cohort.

Key Dates

Keywords

Viracta Therapeutics, Nana-val, EBV-positive lymphoma, PTCL, Clinical Trial, Nanatinostat, Valganciclovir, Oncology, Phase 2, FDA, R&D, Financial Results